APP and Alzheimer disease: As for the non-amyloidogenic pathway, ADAM10 levels are decreased in AD, in an AD mouse model that contains disease-associated mutations in APP, and in primary neurons treated with Aβ [34,35], possibly leading to decreased non-amyloidogenic processing of APP, as evidenced by decreased levels of sAPPα in the CSF of patients with AD [36].